| Literature DB >> 26105539 |
Venkatesh P Kashi1, Mark E Hatley2, Rene L Galindo3.
Abstract
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy composed of neoplastic primitive precursor cells that exhibit histological features of myogenic differentiation. Despite intensive conventional multimodal therapy, patients with high-risk RMS typically suffer from aggressive disease. The lack of directed therapies against RMS emphasizes the need to further uncover the molecular underpinnings of the disease. In this Review, we discuss the notable advances in the model systems now available to probe for new RMS-targetable pathogenetic mechanisms, and the possibilities for enhanced RMS therapeutics and improved clinical outcomes.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26105539 PMCID： PMC4599785 DOI： 10.1038/nrc3961
Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716